Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
18.50
+0.60 (3.35%)
Jun 29, 2026, 2:20 PM EDT - Market open
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Viridian Therapeutics stock have an average target of 35.5, with a low estimate of 22 and a high estimate of 50. The average target predicts an increase of 91.89% from the current stock price of 18.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 14 | 13 | 13 | 14 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 18 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Reiterates $50 → $35 | Buy | Reiterates | $50 → $35 | +89.19% | Jun 29, 2026 |
| Wells Fargo | Wells Fargo | Buy Upgrades $20 → $31 | Buy | Upgrades | $20 → $31 | +67.57% | Jun 29, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $35 | Buy | Maintains | $35 | +89.19% | Jun 29, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 29, 2026 |
| Needham | Needham | Buy Maintains $32 | Buy | Maintains | $32 | +72.97% | Jun 29, 2026 |
Financial Forecast
Revenue This Year
33.62M
from 70.85M
Decreased by -52.55%
Revenue Next Year
244.44M
from 33.62M
Increased by 627.09%
EPS This Year
-3.81
from -3.32
EPS Next Year
-2.51
from -3.81
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 66.2M | 375.5M | |
| Avg | 33.6M | 244.4M | |
| Low | 10.1M | 134.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -6.6% | 1,016.9% | |
| Avg | -52.5% | 627.1% | |
| Low | -85.7% | 298.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.21 | -0.73 | |
| Avg | -3.81 | -2.51 | |
| Low | -4.54 | -4.19 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.